Cargando…

A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients

OBJECTIVE: The economic burden of commercially insured patients in the United States with treatment-resistant depression and patients with non–treatment-resistant major depressive disorder was compared using data from the Optum Clinformatics™ claims database. METHODS: Patients 18–63 years on antidep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Gang, Zhang, Ling, DiBernardo, Allitia, Wang, Grace, Sheehan, John J., Lee, Kwan, Reutfors, Johan, Zhang, Qiaoyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485754/ https://www.ncbi.nlm.nih.gov/pubmed/32915863 http://dx.doi.org/10.1371/journal.pone.0238843

Ejemplares similares

All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population
por: Li, Gang, et al.
Publicado: (2019)

Treatment‐resistant depression as risk factor for substance use disorders—a nation‐wide register‐based cohort study
por: Brenner, Philip, et al.
Publicado: (2019)

Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study
por: Brenner, Philip, et al.
Publicado: (2019)

Humanistic outcomes in treatment resistant depression: a secondary analysis of the STAR*D study
por: DiBernardo, Allitia, et al.
Publicado: (2018)

A register-based approach to identifying treatment-resistant depression—Comparison with clinical definitions
por: Hägg, David, et al.
Publicado: (2020)

Risk and risk factors for disability pension among patients with treatment resistant depression– a matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2020)

Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
por: Elsaid, Mohamed I., et al.
Publicado: (2020)

Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant
por: Kale, Hrishikesh P., et al.
Publicado: (2021)

Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
por: Fu, Alex Z., et al.
Publicado: (2022)

1019. Healthcare Resource Utilization and Cost of People Living with HIV (PLWH) in US Commercial and Medicare Advantage Health Plans
por: Priest, Julie, et al.
Publicado: (2020)

Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
por: Kobayashi, Monica, et al.
Publicado: (2023)

Multiple Comorbidities, Psychiatric Disorders, Healthcare Resource Utilization and Costs Among Adults with Essential Tremor: A Retrospective Observational Study in a Large US Commercially Insured and Medicare Advantage Population
por: Dai, Dingwei, et al.
Publicado: (2022)

Costs of pediatric liver transplantation among commercially insured and Medicaid-insured patients with cholestasis in the US
por: Miloh, Tamir, et al.
Publicado: (2023)

Monthly Cost-Sharing Limits and Out-of-pocket Costs for Commercially Insured Patients in the US
por: Shafer, Paul R., et al.
Publicado: (2022)

Utilization and Costs of Compounded Medications for Commercially Insured Patients, 2012-2013
por: McPherson, Timothy, et al.
Publicado: (2016)

Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims
por: Senna, Maryanne, et al.
Publicado: (2021)

Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults
por: Sahrmann, John M, et al.
Publicado: (2023)

Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019
por: Howe, Sarah J., et al.
Publicado: (2022)

Healthcare Resource Utilization and Costs in Celiac Disease: A US Claims Analysis
por: Cappell, Katherine, et al.
Publicado: (2020)

Patient-reported outcomes in major depressive disorder with suicidal ideation: a real-world data analysis using PatientsLikeMe platform
por: Borentain, Stephane, et al.
Publicado: (2020)

Cost of Treatment in a US Commercially Insured, HIV-1–Infected Population
por: Solem, Caitlyn T., et al.
Publicado: (2014)

Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA
por: Estes, Stephanie J., et al.
Publicado: (2020)

Correction: Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019
por: Howe, Sarah J., et al.
Publicado: (2022)

Utilization and Costs of Gender-Affirming Care in a Commercially Insured Transgender Population
por: Baker, Kellan, et al.
Publicado: (2022)

Costs of Severe Maternal Morbidity in U.S. Commercially Insured and Medicaid Populations: An Updated Analysis
por: Black, Christopher M., et al.
Publicado: (2021)

Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States
por: Kabadi, Shaum M., et al.
Publicado: (2019)

The impact of high-risk and chronic opioid use among commercially insured endometriosis patients on health care resource utilization and costs in the United States
por: Estes, Stephanie J, et al.
Publicado: (2020)

Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population
por: Smith, Spenser, et al.
Publicado: (2022)

Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
por: Olson, Amy L., et al.
Publicado: (2020)

Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database
por: Uzoigwe, Chioma, et al.
Publicado: (2022)

US Health Resource Utilization and Cost Burden Associated with Choroideremia
por: Dong, Shaobin, et al.
Publicado: (2021)

Physical Impairment, Insurance Coverage, and Healthcare Utilization Among U.S. Chinese Older Adults
por: Attilus, Jonas, et al.
Publicado: (2020)

Characteristics and health care utilization of otherwise healthy commercially and Medicaid-insured preterm and full-term infants in the US
por: McLaurin, Kimmie K, et al.
Publicado: (2019)

Utilization patterns and characteristics of users of biologic anti‐inflammatory agents in a large, US commercially insured population
por: Mendelsohn, Aaron B., et al.
Publicado: (2020)

Trends and disparities in the utilization of influenza vaccines among commercially insured US adults during the COVID-19 pandemic
por: Li, Kun, et al.
Publicado: (2022)

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
por: Polsky, Daniel, et al.
Publicado: (2012)

Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 Years
por: Sato, Reiko, et al.
Publicado: (2013)

Ambulatory Health Care Service Use and Costs Among Commercially Insured US Adults With Congenital Heart Disease
por: Agarwal, Anushree, et al.
Publicado: (2020)

Evaluating Costs Associated With Genetic Counseling Among Commercially Insured US Patients With Cancer From 2013 to 2019
por: Roberson, Mya L., et al.
Publicado: (2022)

Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States
por: St. Peter, Wendy L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gq6jr9ugivnaergocrmhahvbds